Vaccinex, Inc.

FOR IMMEDIATE RELEASE

VACCINEX PRESENTS ACTIVMAB ANTIBODY SELECTION TECHNOLOGY AT THE 19TH ANNUAL IBC ANTIBODY ENGINEERING CONFERENCE.

Rochester, NY - December 8, 2008. Vaccinex, Inc. announced today that it has presented a summary of its proprietary ActivMAb antibody discovery technology at the 19th Annual IBC Antibody Engineering Conference in San Diego, CA. Utilizing a vaccinia virus based library technology; ActivMAb enables the efficient selection of fully functional IgG antibodies from highly diverse immunoglobulin gene libraries expressed in mammalian cells. This technology can be used either for de novo selection or for the robust conversion of a non-human antibody into a fully human antibody. This technology has the advantage of a built in selection for full length IgG antibodies that are efficiently expressed in mammalian cells. An additional advantage of this technology is that antibody selection is not restricted by self tolerance. Finally, antibodies from the Vaccinex libraries can be screened for binding to whole cells, enabling discovery of antibodies to proteins that cannot be readily purified. At the conference examples of using this technology to convert a high affinity mouse antibody into a panel of fully human antibodies with equivalent affinity and functional activity, and an example of the de novo selection of high affinity fully human antibodies against a novel breast cancer antigen were presented.

Vaccinex, Inc.

Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of human monoclonal antibodies and other biologics to treat a variety of serious illnesses, including autoimmune disease, inflammation, multiple sclerosis, and cancer. The company's patented ActivMAb® technology allows for the direct selection of high affinity, fully human monoclonal antibodies that would be difficult or impossible to identify using other systems. Vaccinex, on its own or with its partners, has advanced several antibodies from discovery and lead validation into IND-directed pre-clinical drug development. The company is headquartered in Rochester, NY, USA. For more information, please visit www.vaccinex.com.

Contacts

Vaccinex: Raymond E. Watkins, Senior Vice President & COO, 585.271.2700 (x-105)
e-mail: rwatkins@vaccinex.com

Back to News Archive


About Us Executive Team Board of Directors Scientific/ Clinical Advisors Business Strategy Collabora- tions Antibody Technology Overview Membrane Antibody Expression and Selection Secreted IgG Antibody Selection Antibody Animation Development Strategy Development Pipeline


	FOR IMMEDIATE RELEASE VACCINEX PRESENTS ACTIVMAB ANTIBODY SELECTION TECHNOLOGY AT THE 19TH ANNUAL IBC ANTIBODY ENGINEERING CONFERENCE. Rochester, NY - December 8, 2008. Vaccinex, Inc. announced today that it has presented a summary of its proprietary ActivMAb antibody discovery technology at the 19th Annual IBC Antibody Engineering Conference in San Diego, CA. Utilizing a vaccinia virus based library technology; ActivMAb enables the efficient selection of fully functional IgG antibodies from highly diverse immunoglobulin gene libraries expressed in mammalian cells. This technology can be used either for de novo selection or for the robust conversion of a non-human antibody into a fully human antibody. This technology has the advantage of a built in selection for full length IgG antibodies that are efficiently expressed in mammalian cells. An additional advantage of this technology is that antibody selection is not restricted by self tolerance. Finally, antibodies from the Vaccinex libraries can be screened for binding to whole cells, enabling discovery of antibodies to proteins that cannot be readily purified. At the conference examples of using this technology to convert a high affinity mouse antibody into a panel of fully human antibodies with equivalent affinity and functional activity, and an example of the de novo selection of high affinity fully human antibodies against a novel breast cancer antigen were presented. *Vaccinex, Inc. Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of human monoclonal antibodies and other biologics to treat a variety of serious illnesses, including autoimmune disease, inflammation, multiple sclerosis, and cancer. The company's patented ActivMAb® technology allows for the direct selection of high affinity, fully human monoclonal antibodies that would be difficult or impossible to identify using other systems. Vaccinex, on its own or with its partners, has advanced several antibodies from discovery and lead validation into IND-directed pre-clinical drug development. The company is headquartered in Rochester, NY, USA. For more information, please visit www.vaccinex.com. Contacts* Vaccinex: Raymond E. Watkins, Senior Vice President & COO, 585.271.2700 (x-105) e-mail: rwatkins@vaccinex.com Back to News Archive Copyright © 2009 Vaccinex, Inc.